News

Alaxia SAS announced that it has received $1.7 million from the Cystic Fibrosis Foundation Therapeutics (CFFT), the non-profit drug discovery and development arm of the Cystic Fibrosis Foundation (CFF), to support and advance a first clinical study of its inhaled antimicrobial drug candidate, ALX-009, as a therapy for people with cystic fibrosis…

Pulmatrix recently released an educational, animated video to raise awareness of problematic complex lung diseases and to describe encouraging new dry treatment options for patients with lung conditions including cystic fibrosis (CF). The video can be watched here: [ir.pulmatrix.com] It begins “Everyday you take over 20,000 breaths. Imagine if everyone of…

The Boomer Esiason Foundation (BEF), dedicated to increasing awareness, education, and quality of life for people with cystic fibrosis (CF), recently celebrated the 60th birthday of the organization’s CF Ambassador and double lung transplant survivor Jerry Cahill. Cahill, who was told by doctors that he would likely not pass age 16, proves that…

Stem cells from the gut of cystic fibrosis (CF) patients grown in the laboratory could help predict whether a certain treatment will be effective in that particular patient.

Individuals carrying the mutated gene for cystic fibrosis (CF) show an increased risk for asthma, in particular CF carriers from Asian countries. The study, “Risk of asthma in heterozygous carriers for cystic fibrosis: A meta-analysis,” was published in the Journal of Cystic Fibrosis. People with CF are known to have a higher…

Interaction between bacteria naturally occurring in the lungs and disease-causing bacteria may be making it harder to clear the latter from the body, new study finds. This is a major problem especially for people with cystic fibrosis, who are already susceptible to lung infections. The scientists hope that this knowledge will help develop better anti-bacterial therapies for people with cystic fibrosis and other lung conditions.

In March, the U.K. National Institute for Health and Care Excellence (NICE) issued a draft guidance against recommending Orkambi (lumacaftor-ivacaftor marketed by Vertex Pharmaceuticals) for treating cystic fibrosis (CF). The agency’s independent appraisal committee concluded that the cost of Orkambi was considerably higher than the current standard of care, and it could not be…

ProQR Therapeutics is set to release results from a study on the effect of the investigational drug QR-010 on nasal potential difference – an evaluation of CFTR protein function in patients with cystic fibrosis (CF). The findings will be presented at the North American Cystic Fibrosis Conference (NACFC), Oct. 27…

International Biophysics Corporation recently received CE Mark, Health Canada, and Australian TGA approval for AffloVest, allowing the company to sell and market the vest in Canada, Australia and New Zealand, and in countries using the CE mark. The AffloVest is a portable high frequency chest wall oscillation (HFCWO) vest that promotes airway…

Hill-Rom Holdings recently announced the introduction of the VisiVest System – a connected therapeutic garment for patients requiring airway clearance therapy, including patients with cystic fibrosis (CF). The VisiVest System combines innovative high-frequency chest-wall oscillation (HFCWO) technology with wireless connectivity powered by Qualcomm Life. The HFCWO technology consists…